FormBlends Publishes 2026 State of Peptides Report as RFK-Era HHS Signals Major Shifts for GLP-1 and Peptide Therapy Access in the United States
Structure Therapeutics Inc. (GPCR)
Company Research
Source: GlobeNewswire
MIAMI, FL, April 28, 2026 (GLOBE NEWSWIRE) -- FormBlends, a telehealth platform focused on medically supervised GLP-1 therapy and peptide research, today released its 2026 State of Peptides and GLP-1 Regulation report. The report maps how the Robert F. Kennedy Jr. Department of Health and Human Services, the FDA Center for Drug Evaluation and Research, and a pipeline of new obesity drugs from Eli Lilly, Novo Nordisk, Boehringer Ingelheim, and Roche are reshaping what Americans can legally access for weight management, metabolic health, and peptide therapy through the end of the decade. Get the full, more detailed press release version here: https://formblends.com/report/state-of-peptides-and-glp1-regulation-2026 The full report is available at the full report on the FormBlends website and anchors the company's research hub, which brings together FDA guidance documents, bulk substances list updates, ClinicalTrials.gov pipeline data, and plain-English explainers of every compound
Show less
Read more
Impact Snapshot
Event Time:
GPCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GPCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GPCR alerts
High impacting Structure Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
GPCR
News
- Here is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look at [Yahoo! Finance]Yahoo! Finance
- Structure Therapeutics (GPCR) was upgraded by Canaccord Genuity Group Inc. to "strong-buy".MarketBeat
- Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific SessionsGlobeNewswire
- Structure Therapeutics (GPCR) was given a new $101.00 price target by Canaccord Genuity Group Inc..MarketBeat
- Structure Therapeutics (GPCR) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
GPCR
Sec Filings
- 4/23/26 - Form 3
- 4/23/26 - Form 4
- 4/23/26 - Form DEF
- GPCR's page on the SEC website